The team’s now testing their method in more patients.
Gut experts in the U.S. have said, however, that the antibiotic used in this study is not particularly effective against C. diff any more. IDSA and SHEA updated their guidelines in February, recommending that doctors stop using it for C. diff and instead use either vancomycin or fidaxomicin..http://game-rapidshare.com/Wurth-sister-of-Scheinost-from-Telep?Esfahanig=144
This strain is involved in the Yuma romaine outbreak.
Baumhefner said for many patients with breakthrough disease on standard IFNβ-1a, increasing the treatment dosage with twice-weekly therapy may be an acceptable alternative to switching treatments.
June Halper, MSN, MSCN, CMCS CEO, agreed, noting that "it makes a lot of sense for some patients to stay on a drug that has worked for them, and tweak the therapy if there is a breakthrough instead of automatically moving on to another drug," she told MedPage Today.
Baumhefner said a prospective, blinded, randomized trial comparing once-weekly and twice-weekly intramuscular IFNβ-1a may be warranted.